Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

January 5, 2018: By Market Scope

Kala PharmaceuticalsKala Pharmaceuticals announced Jan. 5 that KPI-121 0.25% saw mixed results in its two Phase III clinical trials in dry eye disease, meeting three or four primary endpoints.

Kala CEO Mark Iwicki said the company would need to study the data more to decide the path forward, and he was unable to provide a timetable.

The company said it plans to seek a meeting with US regulators for guidance. Future options include conducting another study or submitting the data as is to the FDA.

The Waltham, Massachusetts, firm said it believes its cash balance of $114 million puts it in a strong position as it continues to advance its candidates.

Kala’s formulations use its mucus-penetrating particle (MPP) technology to enhance penetration of the steroid loteprednol etabonate in eye tissue.

Kala’s lead candidates are KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease; and INVELTYS (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery.

The dry eye candidate achieved statistical significance in both Phase III trials (STRIDE 1 and STRIDE 2) in the primary sign endpoint of improvement in conjunctival hyperemia at Day 15.

It showed statistical significance in the primary symptom endpoint of improvement in ocular discomfort at Day 15 in the first Phase III trial. In the second trial, it showed improvement, but not at a statistically significant level.

The trials were multicenter, randomized, double-masked, placebo-controlled studies comparing KPI-121 with placebo, each dosed four times a day for 14 days.

In both studies, KPI-121 0.25% was well-tolerated, with elevations of intraocular pressure similar to placebo.

Kala also announced Jan. 5 that the FDA had accepted INVELTYS’ submission for review and assigned a target action date of Aug. 24.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023